Dr. Yoshua Esquenazi's laboratory at UTHealth Houston is spearheading three distinct yet complementary research programs, each aimed at advancing our understanding and treatment of gliomas, particularly glioblastoma.

RESEARCH

Gliomas and Gut Microbiome Interactions

Recent studies have revealed a complex interplay between the gut microbiome and gliomas, suggesting that the gut-brain axis may play a crucial role in tumor development, progression, and treatment response. Our research program investigates the complex relationship between gliomas, gut microbiome, and metabolites. Using 16S rRNA sequencing and fecal metabolite analysis in both murine models and glioma patients, our team aims to identify microbiome signatures that could predict patient outcomes. We are also exploring the connection between gut microbiome/metabolites and radiation-induced cognitive deficits, as well as the potential for improving glioma therapies through gut microbiome manipulation. This work is done in collaboration with Dr. Leomar Ballester, MD PhD at MD Anderson Cancer Center.

This emerging field of research holds significant promise for developing novel diagnostic tools, prognostic markers, and therapeutic strategies for glioma patients, potentially revolutionizing the approach to neuro-oncology through microbiome manipulation and metabolite modulation

Cerebrospinal Fluid (CSF) Biomarkers for CNS Tumors

Cerebrospinal fluid (CSF) biomarkers hold immense potential for revolutionizing the diagnosis and management of central nervous system (CNS) tumors, offering a safer and less invasive alternative to traditional brain biopsies.

Our research aims to harness this potential by discovering and validating CSF biomarkers for CNS tumors, focusing on the analysis of circulating tumor DNA (ctDNA), extracellular vesicle microRNAs (EV-miRNAs), and metabolites. A critical aspect of our work is developing biomarkers that can reliably distinguish tumor recurrence from radiation therapy effects, addressing a significant challenge in neuro-oncology and potentially improving treatment decisions and patient outcomes. This work is done in collaboration with Dr. Leomar Ballester, MD PhD at MD Anderson Cancer Center.

Glioma Outcomes Research

We perform retrospective and prospective clinical outcomes studies focused on improving outcomes for patients with glioblastoma and low grade gliomas. We participate in he RANO resect group and IRRF research program to answer important questions about surgical strategies, extent of resection and radiation therapy to improve the care glioma patients receive through extensive collaboration with researchers and clinicians worldwide. This global effort aims to identify prognostic factors, potential therapeutic targets, and develop standardized protocols for glioblastoma management.

Lab Missions

Dr. Yoshua Esquenazi's laboratory at UTHealth Houston is guided by four core missions that reflect his expertise in neurosurgery and neuro-oncology:

  1. Advancing Scientific Integrity and Reproducibility
    Dr. Esquenazi's lab is committed to conducting research of the highest ethical and scientific standards. The team embraces rigorous peer review and constructive criticism, ensuring that their work in glioma research and CSF biomarker development is robust and reproducible. This commitment to scientific integrity is crucial in translating laboratory findings into clinical applications for brain tumor patients.

  2. Nurturing the Next Generation of Neuro-Oncology Experts
    Mentorship is a cornerstone of Dr. Esquenazi's lab. As a neurosurgeon-scientist, he is uniquely positioned to guide students and early-career scientists in both clinical and research aspects of neuro-oncology. The lab provides a supportive environment for professional growth, encouraging team members to develop expertise in cutting-edge techniques such as CSF biomarker analysis and microbiome studies in glioma research.

  3. Fostering Diversity and Inclusion in Neurosurgical-Oncology Research
    The lab recognizes that diversity is a catalyst for innovation in brain tumor research. Dr. Esquenazi cultivates an inclusive environment where team members from various backgrounds contribute their unique perspectives. This diversity of thought is particularly valuable in the lab's global collaborations on glioblastoma clinical outcomes, bringing together varied approaches to tackle complex neuro-oncological challenges.

  4. Pioneering Translational Research for Improved Patient Outcomes
    The ultimate goal of Dr. Esquenazi's lab is to transform patient care in neuro-oncology. By combining his surgical expertise with innovative research on gut microbiome-glioma interactions, CSF biomarkers, and global clinical data analysis, the lab aims to develop novel diagnostic tools, prognostic markers, and treatment strategies. This multidisciplinary approach reflects Dr. Esquenazi's commitment to bridging the gap between laboratory discoveries and clinical applications in brain tumor management.